Inflection Biosciences Ltd
Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer, inflammatory and autoimmune diseases. The company's pipeline was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-101 is a pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML and multiple myeloma. The partnered pipeline comprises AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. For more information please visit Inflection Biosciences Ltd(CNIO)IBL-300PIM/PI3K/mTORIBL-202PIM/PI3KIBL-100PIMInflection Biosciences14
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
6
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Inflection Biosciences Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Inflection Biosciences Ltd
2 distinct titles indexed · top 2 shown.
- 1director
- 1senior clinical scientist
Sign up to unlock all 3 contacts at Inflection Biosciences Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Inflection Biosciences Ltd
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.